Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis

被引：0
|
作者：
George W. Reed
Robert A. Gerber
Ying Shan
Liza Takiya
Kimberly J. Dandreo
David Gruben
Joel Kremer
Gene Wallenstein
机构：
[1] Corrona Research Foundation,
[2] University of Massachusetts Medical School,undefined
[3] Pfizer Inc,undefined
[4] Corrona,undefined
[5] LLC,undefined
[6] Pfizer Inc,undefined
[7] Albany Medical College,undefined
来源：
Rheumatology and Therapy | 2019年 / 6卷
关键词：
Anti-TNF; DMARDs (synthetic); Rheumatoid arthritis; Tofacitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：573 / 586
页数：13
相关论文
共 50 条
  • [31] Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis
    Curtis, Jeffrey R.
    Palmer, J. Lynn
    Reed, George W.
    Greenberg, Jeffrey
    Pappas, Dimitrios A.
    Harrold, Leslie R.
    Kremer, Joel M.
    ARTHRITIS CARE & RESEARCH, 2021, 73 (08) : 1114 - 1124
  • [32] A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor
    Caporali, Roberto
    Kadakia, Aditi
    Howell, Oliver
    Patel, Jayesh
    Milligan, Jack
    Strengholt, Sander
    Barlow, Sophie
    Taylor, Peter C.
    ADVANCES IN THERAPY, 2024, 41 (09) : 3706 - 3721
  • [33] Tumor necrosis factor inhibitors for rheumatoid arthritis
    Dentener, Mieke A.
    Wouters, Emiel F. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (19): : 2047 - 2048
  • [34] Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting
    Mease, Philip J.
    Accortt, Neil A.
    Rebello, Sabrina
    Etzel, Carol J.
    Harrison, Ryan W.
    Aras, Girish A.
    Gharaibeh, Mandi M. F.
    Greenberg, Jeffrey D.
    Collier, David H.
    RHEUMATOLOGY INTERNATIONAL, 2019, 39 (09) : 1547 - 1558
  • [35] Inhibitors of tumor necrosis factor for rheumatoid arthritis
    Moreland, LW
    JOURNAL OF RHEUMATOLOGY, 1999, 26 : 7 - 15
  • [36] Tumor necrosis factor inhibitors for rheumatoid arthritis
    Scott, D. L.
    Kingsley, G. H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (07): : 704 - 712
  • [37] Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting
    Philip J. Mease
    Neil A. Accortt
    Sabrina Rebello
    Carol J. Etzel
    Ryan W. Harrison
    Girish A. Aras
    Mahdi M. F. Gharaibeh
    Jeffrey D. Greenberg
    David H. Collier
    Rheumatology International, 2019, 39 : 1547 - 1558
  • [38] Tumor necrosis factor inhibitors for rheumatoid arthritis
    Jones, RE
    Moreland, LW
    BULLETIN ON THE RHEUMATIC DISEASES, 1999, 48 (03) : 1 - 4
  • [39] Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan
    Hsieh, Song-Chou
    Chen, Yi-Hsing
    Chen, Wei-Sheng
    Tsai, Wen-Chan
    Hu, Jui-Chieh
    Chen, Hsiang-Cheng
    Mardekian, Jack
    Lai, Chacun
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [40] Real-world evidence of tofacitinib in rheumatoid arthritis patients in Spain
    Roman Ivorra, Jose A.
    Llevat, Noelia
    Montoro, Maria
    DRUG DISCOVERIES AND THERAPEUTICS, 2022, 16 (02): : 63 - 71
12345